Literature DB >> 12871652

The mouse Chrna4 A529T polymorphism alters the ratio of high to low affinity alpha 4 beta 2 nAChRs.

Heejeong Kim1, Brody A Flanagin, Chuan Qin, Robert L Macdonald, Jerry A Stitzel.   

Abstract

Previously, a missense polymorphism was identified in the mouse nicotinic receptor alpha4 subunit gene, Chrna4. This polymorphism leads to an Ala/Thr variation at amino acid position 529 of the alpha4 subunit. Chrna4 A529T is associated with several measures of acute sensitivity to nicotine as well as with mouse strain differences in nicotine-stimulated (86)Rb(+) efflux from synaptosomes. Here, we report that the variant forms of the mouse alpha4 subunit confer functional differences when expressed with the beta2 subunit in a heterologous system. alpha4beta2 receptors containing the T529 variant of the alpha4 subunit exhibited a higher EC(50) value for the high affinity receptor population and an apparent reduced sensitivity to blockade by DHbetaE relative to alpha4beta2 receptors containing the A529 variant of the alpha4 subunit. Moreover, the proportion of the total agonist-elicited current contributed by the high affinity alpha4beta2 receptor population was greater for alpha4beta2 receptors containing the alpha4(T529) variant (64%) than the alpha4beta2 receptors containing the alpha4(A529) variant (41%). These data suggest that the polymorphism in the mouse alpha4 subunit is located in a previously unidentified functional domain of the receptor subunit that influences receptor function, including regulation of the affinity population ratio of alpha4beta2 receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871652     DOI: 10.1016/s0028-3908(03)00167-9

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  13 in total

1.  Pentameric concatenated (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) nicotinic acetylcholine receptors: subunit arrangement determines functional expression.

Authors:  A-L Carbone; M Moroni; P-J Groot-Kormelink; I Bermudez
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

2.  Variants in nicotinic receptors and risk for nicotine dependence.

Authors:  Laura Jean Bierut; Jerry A Stitzel; Jen C Wang; Anthony L Hinrichs; Richard A Grucza; Xiaoling Xuei; Nancy L Saccone; Scott F Saccone; Sarah Bertelsen; Louis Fox; William J Horton; Naomi Breslau; John Budde; C Robert Cloninger; Danielle M Dick; Tatiana Foroud; Dorothy Hatsukami; Victor Hesselbrock; Eric O Johnson; John Kramer; Samuel Kuperman; Pamela A F Madden; Kevin Mayo; John Nurnberger; Ovide Pomerleau; Bernice Porjesz; Oliver Reyes; Marc Schuckit; Gary Swan; Jay A Tischfield; Howard J Edenberg; John P Rice; Alison M Goate
Journal:  Am J Psychiatry       Date:  2008-06-02       Impact factor: 18.112

3.  The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.

Authors:  Kristin M Wildeboer-Andrud; Karen E Stevens
Journal:  Pharmacol Biochem Behav       Date:  2011-07-07       Impact factor: 3.533

Review 4.  Genetic matters: thirty years of progress using mouse models in nicotinic research.

Authors:  Michael J Marks
Journal:  Biochem Pharmacol       Date:  2013-06-06       Impact factor: 5.858

5.  Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats.

Authors:  Amir H Rezvani; Marty C Cauley; Edwin C Johnson; Gregory J Gatto; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2012-04-20       Impact factor: 4.530

Review 6.  Natural genetic variability of the neuronal nicotinic acetylcholine receptor subunit genes in mice: Consequences and confounds.

Authors:  Jennifer A Wilking; Jerry A Stitzel
Journal:  Neuropharmacology       Date:  2014-12-09       Impact factor: 5.250

Review 7.  Translational research in nicotine dependence.

Authors:  Jill R Turner; Allison Gold; Robert Schnoll; Julie A Blendy
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

8.  Non-agonist-binding subunit interfaces confer distinct functional signatures to the alternate stoichiometries of the alpha4beta2 nicotinic receptor: an alpha4-alpha4 interface is required for Zn2+ potentiation.

Authors:  Mirko Moroni; Ranjit Vijayan; Anna Carbone; Ruud Zwart; Philip C Biggin; Isabel Bermudez
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

Review 9.  nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Authors:  Vinay Parikh; Munir Gunes Kutlu; Thomas J Gould
Journal:  Schizophr Res       Date:  2016-01-21       Impact factor: 4.939

10.  Chrna4 A529 knock-in mice exhibit altered nicotine sensitivity.

Authors:  Jennifer A Wilking; Kirstin G Hesterberg; Eric L Crouch; Gregg E Homanics; Jerry A Stitzel
Journal:  Pharmacogenet Genomics       Date:  2010-02       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.